Natural Killer Cell Therapy to Be Studied in Blood Cancers

A phase 1 trial recently kicked off evaluating the novel drug, IDP-023 for the treatment of patients with relapsed or refractory multiple myeloma and non-Hodgkin lymphoma, according to a news release issued by Indapta Therapeutics, the manufacturer of the drug.

Read the full article